Prophylaxis News and Research

RSS

Prophylaxis treatment can protect children who receive liver transplants from HBV-infected donors

Researchers have found that a prophylaxis treatment can prevent new-onset hepatitis B in children who receive liver transplants from donors who were previously infected with hepatitis B virus (HBV) but had successfully cleared the virus.

16 Dec 2015

Study: Preoperative use of blood-thinning drugs associated with decreased risk of blood clots

Among patients undergoing major cancer operations, the preoperative use of blood-thinning drugs such as heparin does not increase rates of major bleeding or transfusions, and is associated with a decreased risk of blood clots, according to new study results published online in the Journal of the American College of Surgeons ahead of print publication early next year.

16 Dec 2015

VistaPharm announces launch of Potassium Chloride Solution

VistaPharm today announced that it has launched Potassium Chloride Solution, USP, 10% in Unit Dose. The product is supplied to the market in a 50 count case of 30mL unit dose cups.

14 Dec 2015

Providing novice surgeons with regular feedback can help prevent blood clots among hospitalized patients

A study of general surgery residents at The Johns Hopkins Hospital suggests that in the efforts to prevent dangerous blood clots among hospitalized patients, regular, one-on-one feedback and written report cards work a lot better than the usual group lectures that newly minted surgeons receive as part of their training.

11 Dec 2015

New framework launched for global elimination of human rabies

A new framework to eliminate human rabies and save tens of thousands of lives each year has been launched today by the World Health Organization, the World Organization for Animal Health, the Food and Agriculture Organization of the United Nations and the Global Alliance for the Control of Rabies.

10 Dec 2015

WHO highlights need to expand antiretroviral therapy, reverse HIV epidemic on World AIDS Day

On World AIDS Day the World Health Organization emphasizes that expanding antiretroviral therapy to all people living with HIV is key to ending the AIDS epidemic within a generation.

7 Dec 2015

Prophylactic antibiotics reduce risk of serious bacterial infections in children with ALL

Prophylactic antibiotics significantly reduce the risk of serious bacterial infections in children during the critical first month of treatment for acute lymphoblastic leukemia (ALL), the most common childhood cancer, according to a U.S. and Canadian study led by investigators from Dana-Farber/Boston Children's Cancer and Blood Disorders Center.

7 Dec 2015

WHO recommends new strategies to treat HIV patients, reduce new infections

The world is poised to end the AIDS epidemic by 2030 – provided it can accelerate the pace of progress achieved globally over the past 15 years, according to a new World Health Organization (WHO) report.

1 Dec 2015

Boston Scientific obtains FDA approval, CE Mark for AngioJet ZelanteDVT catheter to treat DVT

Boston Scientific has received United States (U.S.) Food and Drug Administration approval and CE Mark for the AngioJet ZelanteDVT thrombectomy catheter to treat deep vein thrombosis (DVT) in large-diameter upper and lower limb peripheral veins.

30 Nov 2015

Incidence of HIV in Europe reaches record high

Results of recent surveillance conducted by the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe indicate that the annual number of newly diagnosed HIV infections in Europe reached an all-time high in 2014.

27 Nov 2015

12 months of liquid formula HIV drugs protect breastfeeding babies against HIV infection

A study from four countries in Africa, published in The Lancet, shows that providing babies with up to 12 months of liquid formula HIV drugs, while breastfeeding with their HIV-positive mothers, is highly effective at protecting them from infection, including in the 6–12 month period after birth which has not been analysed in previous research.

20 Nov 2015

Gamma interferon may have potential to prevent Ebola infection

The recent Ebola outbreak in West Africa has claimed more than 11,300 lives and starkly revealed the lack of effective options for treating or preventing the disease. Progress has been made on developing vaccines, but there is still a need for antiviral therapies to protect health care workers and local populations in the event of future outbreaks.

18 Nov 2015

Study: Safe spaces may play critical role in community-based HIV prevention efforts

The creation and sustainment of "safe spaces" may play a critical role in community-based HIV prevention efforts by providing social support and reducing environmental barriers for vulnerable populations, a new study from an Oregon State University researcher has found.

17 Nov 2015

Adynovate approved for patients with Hemophilia A

The U.S. Food and Drug Administration today approved Adynovate, Antihemophilic Factor (Recombinant), PEGylated for use in adults and adolescents, aged 12 years and older, who have Hemophilia A. Adynovate is modified to last longer in the blood and potentially require less frequent injections than unmodified Antihemophilic Factor when used to reduce the frequency of bleeding.

15 Nov 2015

Personalized approach to treating side-effects of chemotherapy better for cancer patients

A new research study led by Dr. Mark Clemons, oncologist and associate cancer research scientist at The Ottawa Hospital, has shown that a personalized approach to treating one of the most expected side-effects of chemotherapy is far more effective than the existing "one size fits all" set of guidelines.

13 Nov 2015

New data validates use of ActiveCare DVT prophylaxis compression system following total joint replacement surgery

Medical Compression Systems, Inc. (MCS), today announced new data further validating the use of the ActiveCare DVT prophylaxis compression system following total joint replacement procedures.

11 Nov 2015

Boehringer Ingelheim announces FDA approval of Praxbind (idarucizumab)

Boehringer Ingelheim Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration granted approval of Praxbind (idarucizumab). PRAXBIND is indicated for patients treated with Pradaxa (dabigatran etexilate mesylate), when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding.

16 Oct 2015

Antibiotic resistance potentially threatens the safety and efficacy of surgical procedures and immunosuppression therapies

This week The Lancet Infectious Diseases journal published the strongest evidence to date that increasing antibiotic resistance could have disastrous consequences for patients undergoing surgery or cancer chemotherapy. Based on a review of published literature, researchers predict that a 30% reduction in the efficacy of the prophylactic antibiotics routinely given when these procedures are performed could result in 120,000 more infections and 6300 infection-related deaths every year in the USA alone.

16 Oct 2015

Safe, effective douche-based rectal microbicide can prevent HIV in gay men

Enemas are commonly used by men who have sex with men (MSM) and transwomen (TW) before sexual intercourse. But these groups are vulnerable to HIV and a host of other sexually transmitted infections because enemas -- even those that use tap water -- can seriously damage the thin tissue lining the rectum, allowing for easier transmission of harmful viruses and bacteria.

16 Oct 2015

Genocea announces positive data in Phase 2 trial evaluating GEN-003 for the treatment of genital herpes

Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study.

7 Oct 2015

Prophylaxis News and Research

Prophylaxis treatment can protect children who receive liver transplants from HBV-infected donors

Study: Preoperative use of blood-thinning drugs associated with decreased risk of blood clots

VistaPharm announces launch of Potassium Chloride Solution

Providing novice surgeons with regular feedback can help prevent blood clots among hospitalized patients

New framework launched for global elimination of human rabies

WHO highlights need to expand antiretroviral therapy, reverse HIV epidemic on World AIDS Day

Prophylactic antibiotics reduce risk of serious bacterial infections in children with ALL

WHO recommends new strategies to treat HIV patients, reduce new infections

Boston Scientific obtains FDA approval, CE Mark for AngioJet ZelanteDVT catheter to treat DVT

Incidence of HIV in Europe reaches record high

12 months of liquid formula HIV drugs protect breastfeeding babies against HIV infection

Gamma interferon may have potential to prevent Ebola infection

Study: Safe spaces may play critical role in community-based HIV prevention efforts

Adynovate approved for patients with Hemophilia A

Personalized approach to treating side-effects of chemotherapy better for cancer patients

New data validates use of ActiveCare DVT prophylaxis compression system following total joint replacement surgery

Boehringer Ingelheim announces FDA approval of Praxbind (idarucizumab)

Antibiotic resistance potentially threatens the safety and efficacy of surgical procedures and immunosuppression therapies

Safe, effective douche-based rectal microbicide can prevent HIV in gay men

Genocea announces positive data in Phase 2 trial evaluating GEN-003 for the treatment of genital herpes

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News